227 related articles for article (PubMed ID: 26392489)
1. Role of Semen on Vaginal HIV-1 Transmission and Maraviroc Protection.
Council OD; Swanson MD; Spagnuolo RA; Wahl A; Garcia JV
Antimicrob Agents Chemother; 2015 Dec; 59(12):7847-51. PubMed ID: 26392489
[TBL] [Abstract][Full Text] [Related]
2. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.
Neff CP; Kurisu T; Ndolo T; Fox K; Akkina R
PLoS One; 2011; 6(6):e20209. PubMed ID: 21673796
[TBL] [Abstract][Full Text] [Related]
3. Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.
Destache CJ; Mandal S; Yuan Z; Kang G; Date AA; Lu W; Shibata A; Pham R; Bruck P; Rezich M; Zhou Y; Vivekanandan R; Fletcher CV; Li Q
Antimicrob Agents Chemother; 2016 Jun; 60(6):3633-9. PubMed ID: 27044548
[TBL] [Abstract][Full Text] [Related]
4. ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions.
Olesen R; Swanson MD; Kovarova M; Nochi T; Chateau M; Honeycutt JB; Long JM; Denton PW; Hudgens MG; Richardson A; Tolstrup M; Østergaard L; Wahl A; Garcia JV
J Clin Invest; 2016 Mar; 126(3):892-904. PubMed ID: 26854925
[TBL] [Abstract][Full Text] [Related]
5. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity.
Pulido I; Machmach K; Romero-Sánchez MC; Genebat M; Mendez-Lagares G; Ruiz-Mateos E; Leal M
J Infect; 2012 Apr; 64(4):417-23. PubMed ID: 22227467
[TBL] [Abstract][Full Text] [Related]
6. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.
MacArthur RD; Novak RM
Clin Infect Dis; 2008 Jul; 47(2):236-41. PubMed ID: 18532888
[TBL] [Abstract][Full Text] [Related]
7. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.
Denton PW; Estes JD; Sun Z; Othieno FA; Wei BL; Wege AK; Powell DA; Payne D; Haase AT; Garcia JV
PLoS Med; 2008 Jan; 5(1):e16. PubMed ID: 18198941
[TBL] [Abstract][Full Text] [Related]
9. Antiviral effect of maraviroc in semen: a case report.
Pasquier C; Moinard N; Sauné K; Daudin M; Trancart S; Massip P; Izopet J; Bujan L
Antivir Ther; 2012; 17(5):933-6. PubMed ID: 22297568
[TBL] [Abstract][Full Text] [Related]
10. Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.
Sepúlveda-Crespo D; Sánchez-Rodríguez J; Serramía MJ; Gómez R; De La Mata FJ; Jiménez JL; Muñoz-Fernández MÁ
Nanomedicine (Lond); 2015; 10(6):899-914. PubMed ID: 25867856
[TBL] [Abstract][Full Text] [Related]
11. Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
Fox J; Tiraboschi JM; Herrera C; Else L; Egan D; Dickinson L; Jackson A; Olejniczak N; Back D; Khoo S; Shattock R; Boffito M
J Acquir Immune Defic Syndr; 2016 Nov; 73(3):252-257. PubMed ID: 27727157
[TBL] [Abstract][Full Text] [Related]
12. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
[TBL] [Abstract][Full Text] [Related]
13. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
Seclén E; González Mdel M; Lapaz M; Rodríguez C; del Romero J; Aguilera A; de Mendoza C; Soriano V; Poveda E
J Antimicrob Chemother; 2010 Dec; 65(12):2502-4. PubMed ID: 20940179
[TBL] [Abstract][Full Text] [Related]
14. A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.
Kovarova M; Swanson MD; Sanchez RI; Baker CE; Steve J; Spagnuolo RA; Howell BJ; Hazuda DJ; Garcia JV
J Antimicrob Chemother; 2016 Jun; 71(6):1586-96. PubMed ID: 27002074
[TBL] [Abstract][Full Text] [Related]
15. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
Cooper DA; Heera J; Goodrich J; Tawadrous M; Saag M; Dejesus E; Clumeck N; Walmsley S; Ting N; Coakley E; Reeves JD; Reyes-Teran G; Westby M; Van Der Ryst E; Ive P; Mohapi L; Mingrone H; Horban A; Hackman F; Sullivan J; Mayer H
J Infect Dis; 2010 Mar; 201(6):803-13. PubMed ID: 20151839
[TBL] [Abstract][Full Text] [Related]
16. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.
Neff CP; Ndolo T; Tandon A; Habu Y; Akkina R
PLoS One; 2010 Dec; 5(12):e15257. PubMed ID: 21203568
[TBL] [Abstract][Full Text] [Related]
17. Impact of antiretroviral therapy duration and intensification on isolated shedding of HIV-1 RNA in semen.
Osborne BJ; Sheth PM; Yi TJ; Kovacs C; Benko E; Porte Cl; Huibner S; Le AQ; Danroth R; Baraki B; Mazzulli T; Brumme ZL; Kaul R
J Infect Dis; 2013 Apr; 207(8):1226-34. PubMed ID: 23329849
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
19. Modeling HIV-1 Mucosal Transmission and Prevention in Humanized Mice.
Veselinovic M; Charlins P; Akkina R
Methods Mol Biol; 2016; 1354():203-20. PubMed ID: 26714714
[TBL] [Abstract][Full Text] [Related]
20. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
Hunt JS; Romanelli F
Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
